Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.
作者信息
Lyman Gary H, Kuderer Nicole M, Freedland Stephen J
出版信息
J Natl Cancer Inst. 2009 Apr 15;101(8):543-5. doi: 10.1093/jnci/djp060. Epub 2009 Apr 7.
Abstract
摘要
相似文献
1
Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.
J Natl Cancer Inst. 2009 Apr 15;101(8):543-5. doi: 10.1093/jnci/djp060. Epub 2009 Apr 7.
2
Provider treatment intensity and outcomes for patients with early-stage bladder cancer.
J Natl Cancer Inst. 2009 Apr 15;101(8):571-80. doi: 10.1093/jnci/djp039. Epub 2009 Apr 7.
3
Mammography utilization, public health impact, and cost-effectiveness in the United States.
Annu Rev Public Health. 1993;14:605-33. doi: 10.1146/annurev.pu.14.050193.003133.
4
Area variation in Medicare physician spending.
Health Aff (Millwood). 1992 Spring;11(1):224-34. doi: 10.1377/hlthaff.11.1.224.
5
Costs of therapeutic alternatives: physicians' knowledge.
Ann Pharmacother. 1996 Jul-Aug;30(7-8):882-3. doi: 10.1177/106002809603000732.
6
Appropriate, quality imaging tests through linkage of payment to guidelines, accreditation and training.
CMAJ. 2015 Mar 3;187(4):E126-E127. doi: 10.1503/cmaj.140638. Epub 2014 Aug 25.
7
Should cost of care be considered in a clinical practice guideline?
J Natl Compr Canc Netw. 2008 Mar;6(3):224-6. doi: 10.6004/jnccn.2008.0020.
8
Defibrillation testing: the need for a definitive trial.
J Cardiovasc Electrophysiol. 2010 Feb;21(2):183-5. doi: 10.1111/j.1540-8167.2009.01620.x. Epub 2009 Oct 5.
9
[Medical and economic cost of bladder cancer in France].
Rev Prat. 2014 Dec;64(10):1381.
10
The dangers of incorporating reimbursement data into clinical decision making.
Pract Radiat Oncol. 2015 Jul-Aug;5(4):274-6. doi: 10.1016/j.prro.2015.01.002. Epub 2015 Feb 18.
本文引用的文献
1
Provider treatment intensity and outcomes for patients with early-stage bladder cancer.
J Natl Cancer Inst. 2009 Apr 15;101(8):571-80. doi: 10.1093/jnci/djp039. Epub 2009 Apr 7.
2
Bladder cancer.
J Natl Compr Canc Netw. 2009 Jan;7(1):8-39. doi: 10.6004/jnccn.2009.0002.
3
Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project.
J Urol. 2008 Aug;180(2):520-4; discussion 524. doi: 10.1016/j.juro.2008.04.016. Epub 2008 Jun 11.
4
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
J Urol. 2007 Dec;178(6):2314-30. doi: 10.1016/j.juro.2007.09.003.
5
Volume, process of care, and operative mortality for cystectomy for bladder cancer.
Urology. 2007 May;69(5):871-5. doi: 10.1016/j.urology.2007.01.040.
6
Mortality after major surgery for urologic cancers in specialized urology hospitals: are they any better?
J Clin Oncol. 2006 May 1;24(13):2006-12. doi: 10.1200/JCO.2005.04.2622.
7
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. doi: 10.1016/j.eururo.2005.12.031. Epub 2006 Jan 17.
8
Impact of hospital and surgeon volume on in-hospital mortality from radical cystectomy: data from the health care utilization project.
J Urol. 2005 May;173(5):1695-700. doi: 10.1097/01.ju.0000154638.61621.03.
9
Adherence to surveillance among patients with superficial bladder cancer.
J Natl Cancer Inst. 2003 Apr 16;95(8):588-97. doi: 10.1093/jnci/95.8.588.
10
Patterns of care for the treatment of bladder cancer.
J Urol. 2003 May;169(5):1697-701. doi: 10.1097/01.ju.0000056727.30546.b7.
Zotero 插件